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Background: Allergic rhinitis is a chronic respiratory disorder with a detrimental
impact on health-related quality of life (HRQOL) and health status. Enhancement
and maintenance of patient function and well-being are therefore considered
as essential.
Objective: To determine whether long-term treatment with levocetirizine 5mg
improves HRQOL and health status in persistent allergic rhinitis (PER) patients
assessed with RQLQ and SF-36 scales over a 6-month period.
Methods: The Xyzals in PER Trial (XPERTTM) was a multi-center, double-blind,
parallel-group study. A total of 551 patients were randomized to receive
levocetirizine 5mg or placebo once daily for 6 months and assessed for symptoms,
HRQOL (Rhinoconjunctivitis Quality of Life Questionnaire: RQLQ) and health status
(SF-36). Sensitivity of the RQLQ and SF-36 to disease severity was tested to ensurePublished by Elsevier Ltd.
Farchim, Chemin de Croix Blanche, Bulle, Switzerland.
3538931/+39 010 3538933; fax: +39 010 3538904.
(G. Walter Canonica).
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repeated measures analyses.
Results: Over the 6-month treatment period, levocetirizine showed statistically
significant improvements over placebo in HRQOL (Po0:001 for all RQLQ domains and
overall scores) and health status (Pp0:004 for SF-36 physical and mental summary
scores; Po0:05 for all SF-36 scales). The relative improvement of levocetirizine over
placebo exceeded the predefined clinically meaningful threshold of 30% for all RQLQ
scores and the improvement from baseline was 3 times the established MID for RQLQ.
Conclusion: The RQLQ and SF-36 could be used to measure HRQOL and health status
in PER patients. Long-term treatment with levocetirizine provides sustained
improvement of HRQOL and reduces disease burden in PER patients.
& 2006 Published by Elsevier Ltd.Introduction
Allergic rhinitis (AR) is a common chronic respira-
tory disease affecting 10–40% of the population
worldwide.1,2 Its prevalence has been increasing
regularly for many years, doubling within 10 years.3
AR is a disease of bothersome symptoms, such as
rhinorrhea, sneezing, nasal congestion, itching of
the nose and/or conjunctivitis and is often asso-
ciated with comorbid disorders including asthma,
chronic sinusitis, otitis media, and lower respira-
tory tract infection.4 The management of allergic
rhinitis involves reducing the causes (allergen
avoidance, immunotherapy) and controlling the
manifest symptoms (pharmacotherapy).5,6 The
first-line treatment for the control of symptoms is
administration of H1-receptor antagonists.
7
AR may significantly impair patient’s health-
related quality of life (HRQOL), a component of
overall quality of life that reflects the impact of
disease and treatment on patient’s physical and
emotional functioning and well-being.8–10 It has
been recognized as an essential outcome measure
that complements clinical assessments to support
treatment decisions.11,12 Since AR can adversely
affect daily activities, sleep patterns, mental and
social functioning, work and school-related perfor-
mance, which consequently result in substantial
social and economic costs,13–15 the enhancement
and maintenance of patients’ HRQOL are consid-
ered as essential in the treatment of AR.
AR was traditionally classified as seasonal (SAR)
and perennial (PAR) allergic rhinitis based on time
of exposure. This classification, however, did not
entirely correspond to the patients’ pattern of AR
symptoms as patients with perennial symptoms
quite often also have seasonal exacerbations and
additionally, not all patients with PAR have symp-
toms present during the whole year.16 To meet
these concerns, the World Health Organization
Initiative on Allergic Rhinitis and its Impact onAsthma (ARIA, 2001) suggested a new classification
of AR as ‘‘intermittent’’ (IAR) or ‘‘persistent’’ (PER)
based on the frequency and duration of symp-
toms.17 Persistent corresponds to symptoms pre-
sent for more than 4 days a week and for more than
4 weeks, suggesting the presence of chronic
inflammation whereas intermittent corresponds to
symptoms present less than 4 days a week or for
less than 4 weeks. This classification has been
recently validated.18,19
Until recently, the effect of an H1-antihistamine
on HRQOL and health status was not studied in AR
patients diagnosed according to the newly defined
ARIA classification. The Xyzals in Persistent Rhinitis
Trial (XPERTTM) was the first large study investigat-
ing the effects of a modern H1-antihistamine in the
treatment of PER, as defined by ARIA, over a
6–month period.20 The study compared the impact
of levocetirizine 5mg, a potent new-generation
antihistamine, and placebo on efficacy, safety,
HRQOL (measured using the Rhinoconjunctivitis
Quality of Life Questionnaire: RQLQ) and health
status (measured using the Medical Outcomes
Survey Short Form 36: SF-36). This study showed
that treatment with levocetirizine led to significant
symptom relief and provided a fast and sustained
improvement of the HRQOL and health status in
patients with PER. However, since the primary aim
of the XPERT study was to evaluate the effect of
treatment on symptoms and HRQOL after 4 weeks’
treatment, the individual RQLQ domains and the
SF-36 scales were not presented over the entire
study period.20
An important aspect of assessments that are
repeated over time, however, is that they may be
dependent on each other. It has been suggested
that repeated assessments over time should be
subjected to analysis using a longitudinal modeling
approach.21 Furthermore, when questionnaires are
used for the first time in a newly defined patient
population, the sensitivity of the questionnaires in
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ferent levels of disease severity should be tested.21
Consequently, the main objectives of this explora-
tory study were to determine how improvements in
HRQOL and health status noted in PER patients
treated with levocetirizine 5mg daily were trans-
lated into the RQLQ domains and SF-36 scales and
to address the time issue for analysis of HRQOL and
health status in the XPERT study, by comparing the
treatment effects on the RQLQ and SF-36 scores
over the 6–month period as a whole. Additionally,
the sensitivity of the RQLQ and SF-36 to the disease
severity of PER patients was addressed.Materials and methods
XPERT was a multinational, double-blind, rando-
mized study comparing the impact on HRQOL,
efficacy and safety of levocetirizine 5mg versus
placebo administered once daily over a 6–month
period in PER. At an initial visit, patients were
included in the study if they reported PER
symptoms (i.e., rhinitis lasting 4 days or more per
week for 4 consecutive weeks or more per year)
and were sensitized to both house dust mites and
pollen. At the randomization visit 1 week later,
patients were enrolled provided their Total 5
Symptoms Score (i.e., sneezing, rhinorrhea, itchy
nose, itchy eyes and nasal congestion) evaluated
over the selection week was X 6 (max ¼ 15) for at
least 4 days. During the treatment period, patients
attended five visits, 1 and 4 weeks, 3, 4.5 and 6
months after the randomization visit. Authorized
rescue medications were nasal or ocular cromogly-
cate after 1 week of treatment, and prednisolone
(20mg/day for 5 days twice during the study) after
4 weeks. Symptoms, HRQOL and health status were
recorded by the patients using an electronic diary
(Minidocs, Arracel, Sittingbourne, UK). The elec-
tronic mode of administration of HRQOL question-
naires has shown advantages in terms of accuracy
and quality of data collection, compared to the
paper version.22–24
The study protocol was approved by independent
ethics committees and all participants signed an
informed consent form prior to study entry.
Health-related quality of life assessment
HRQOL was assessed by means of the self-adminis-
tered version of the RQLQ.25 The questionnaire was
completed at the beginning of the randomization
visit and at each visit during the treatment period
or at the end of study treatment in case ofwithdrawal. The RQLQ is a disease-specific, vali-
dated instrument for evaluating HRQOL on the basis
of how symptoms and treatment affect patient’s
physical, social and emotional well-being. It com-
prises 28 items combined in 7 domains (activity
limitations, emotional function, eye symptoms,
non-hayfever symptoms, nasal symptoms, practical
problems and sleep problems). Patients were asked
to recall their experiences during the previous
week and to give their responses on 7–point scales
ranging from 0 (i.e. not troubled/none of the time)
to 6 (i.e. extremely troubled/all the time). Results
were expressed as the mean score of all the items
(overall RQLQ score) and the mean score of the
items within each domain (domain score). A high
score indicates a poor quality of life.Health status assessment
Health status was assessed using the self-adminis-
tered SF-36. The questionnaire was completed at
the beginning of the randomization visit and at
each visit during the treatment period except after
1 week or at the end of study treatment in case of
withdrawal. The SF-36 is a generic questionnaire
that has been validated and widely used. It is
composed of 35 items measuring 8 health concepts
(or scales), and 1 reported health transition item.
The 8 health concepts (physical functioning, role-
physical, bodily pain, general health, vitality, social
functioning, role-emotional and mental health) are
summarized in two components, one physical (PCS)
and one mental (MCS). Patients were asked to
recall their experience during the month preceding
the visit and to mark their responses using ordinal
scales or ‘‘yes/no’’ formats. Scoring of SF-36 items
and scales was carried out according to the
instructions described in the SF-36 Health Survey
Manual.26 Scale scores range from 0 to 100, with
100 indicating the most favorable health status.
The aggregated PCS and MCS scores are standar-
dized to have a mean of 50 and a standard
deviation of 10.27Symptom severity assessments
Each evening, patients were asked to score
symptoms of PER (sneezing, rhinorrhea, itchy nose,
itchy eyes and nasal congestion) occurring in the
last 24 h on a 4–point scale: 0 ¼ absent; 1 ¼ mild;
2 ¼ moderate and 3 ¼ severe. The sum of each of
the 5 symptoms, i.e. T5SS, was used to assess the
PER severity and subsequently the sensitivity of the
RQLQ and SF-36 questionnaires to disease severity
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symptoms) and 15 (most severe symptoms).Statistical analysis
A total sample size of 500 patients was planned to
detect a treatment difference of 0.36 in the change
from baseline of the RQLQ overall score after 4
weeks with a power of 87%, an overall alpha error
of 5% and a standard deviation of 1.3. This
difference corresponded to a 40% improvement
over placebo, assuming an improvement from
baseline for placebo of 0.9. All analyses were
performed on the intention-to-treat population
(ITT). Last Observation Carried Forward method
was applied in order to replace missing HRQOL and
health status data.
The sensitivity of the questionnaires to PER
severity was assessed by means of analyses of
variance comparing the scores at baseline (i.e.
randomization visit) across four severity groups
created on the basis of the 25th, 50th and 75th
percentiles of the mean T5SS between selection
and randomization visits. The global treatment
effect over the 6–month period was estimated from
repeated measures analyses on the change in scores
from baseline with treatment, country and visit
(time effect) as factors, treatment by visit inter-
action, and baseline scores as covariate.2
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Baseline characteristics
Data for the two treatment groups (273 patients in
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regard to HRQOL and health status.
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G. Walter Canonica et al.1710the severity of disease, defined using the T5SS over
the week before baseline. While patients with
greatest T5SS (most severe disease) showed the
greatest impairments in their RQLQ and SF-36
scores, the patients with lowest T5SS (least severe
disease) showed lowest impairments. The only
exception to this finding was noted for the SF-36
score for bodily pain, which was found to be highest
for the patient group with the second least severe
disease severity level (Fig. 2).
Comparison of the mean overall and individual
domain scores of the RQLQ for the different
severities showed that these were all significantly
different between the four severity groups (all
Po0:001) (Fig. 1). Similarly, comparison of the
overall physical and mental component summary
scores and individual scale scores of the SF-36
showed that these were all significantly different
between the different severity groups (all
Po0:001, except for the SF-36 bodily pain and
general health scales: Po0:05) (Fig. 2).
Additionally, analyses of the RQLQ individual
domain scores showed that activities, practical
problems, nasal symptoms, and to a lesser extent
eye symptoms domains were the most impaired, as
compared to the other RQLQ domains, across all
disease severity levels (Fig. 1). For the SF-36, the
role-physical, vitality, and role-emotional scale
scores were the most impaired across all disease
severity levels when comparing SF-36 scores to
each other (Fig. 2).Global treatment effect over the 6–month
treatment period
Adjusted mean changes from baseline over the
6–month treatment period are presented in Fig. 3
for the RQLQ overall and domain scores and in
Fig. 4 for the SF-36 component summary and scales
scores. Levocetirizine led to significantly greater
improvements than placebo over the entire treat-
ment period for all scores of both questionnaires
(RQLQ: all Po0:001 for the domain and overall
scores; SF-36: Po0:001 for PCS, P ¼ 0:004 for MCS,
all Po0:05 for the scales).
The relative improvement for levocetirizine over
placebo for the whole treatment period was 36.4%
for the RQLQ overall score and ranged from 31.3%
to 40.8% for the RQLQ domain scores, of which
improvements for activities (38.5%), emotions
(37.4%), eye symptoms (40.2%), nasal symptoms
(40.3%), and sleep (40.8%) were of similar magni-
tude. Since all the RQLQ domain and overall scores
exceeded the predefined threshold of 30% for
clinical significance, the improvements in HRQOL
overall and individual domain scores noted for
levocetirizine were deemed to be clinically rele-
vant. With respect to the SF-36 scores, the
differences in mean changes in scores between
treatment groups were shown to be particularly
large for the role-physical and role-emotional
scales (placebo minus levocetirizine: 9.92 and
7.16, respectively).
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Levocetirizine improves HRQOL and health status in PER 1711With one exception, the time effect was also
statistically significant for all scores (RQLQ: all
Po0:001 for the domain and overall scores; SF-36:
Po0:001 for PCS and MCS, all Po0:05 for the scalesexcept general health), indicating that mean
changes in scores from baseline were more pro-
nounced over time. No statistically significant
treatment by time interaction was found for any
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G. Walter Canonica et al.1712RQLQ or SF-36 score, showing that differences in
mean changes in scores from baseline between
treatment groups were similar over time, with
higher improvements noted for levocetirizine at all
visits. Figure 5 illustrates these results for the RQLQ
overall score.Discussion
It is now recognized that management of allergic
rhinitis should be aimed at reducing impairments
considered important by the patient, including
those associated with comorbid disorders.15,28 It
has also been advocated that the intensity of
HRQOL deterioration should first be taken into
account rather than severity of AR symptoms to
determine the level of treatment.29 Regarding PER,
symptoms are, by definition, chronic and have been
shown to have a huge impact on the HRQOL and
health status of house dust mite sensitive rhinitis
subjects with symptoms for most of the year.30
More recently, XPERT was the first study to
investigate the long-term treatment effect of an
antihistamine, levocetirizine 5mg, on HRQOL and
health status in PER patients, as defined by the
ARIA guidelines.20 The HRQOL and health status
were assessed by means of the RQLQ 25 and the SF-
36,26 two well-validated and widely used ques-
tionnaires considered as complementary to providea multi-perspective view of illness burden.9 Treat-
ment with levocetirizine 5mg once daily signifi-
cantly improved the RQLQ overall score from week
1 to 6 months, compared with placebo. Similarly,
levocetirizine also significantly improved the SF-36
physical component summary scores from weeks 4
to 6 months and the mental component summary
scores after 3 months and 4.5 months of treatment,
compared with placebo.20 The levocetirizine-
mediated improvements in HRQOL and health
status of PER patients is of particular relevance,
because a comparison of the extent of HRQOL
impairment experienced by house dust mite-sensi-
tized PER subjects and controls has indicated that
the PER patients were significantly more distressed
than controls in the RQLQ nose and eye symptoms
domains as well as in the non-hayfever domain for
all seasons during the year.30 Additionally, PER
patients were also characterized by significantly
lower scores in the SF-36 general health and vitality
scales in autumn and in the role-physical and role-
emotional scales in the other seasons. Similarly,
comparisons of the XPERT baseline SF-36 scale
scores with the norms of the general US population
has shown that the burden of PER was marked,
being the largest for the role-physical, the role-
emotional and the social functioning scales.31
The present study builds on the XPERT study. The
findings from this study clearly demonstrate that
the overall degree of impairment in both the
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related to the severity of disease, defined accord-
ing to the T5SS noted for these patients during the
week before baseline. Furthermore, this study
showed that activities, practical problems, nasal
symptoms and eye symptoms domains of the RQLQ,
and role-physical, vitality, and role-emotional
scales of the SF-36 were most impaired across all
disease severity levels in PER. Assessment of the
treatment effects using the RQLQ and SF-36 in the
XPERT study showed that levocetirizine led to
statistically significant larger improvements of
HRQOL and health status than placebo over the
whole treatment duration in PER. This was true for
all RQLQ domains and the overall score, despite
substantial improvements in the placebo group, as
well as for all SF-36 scales and the two summary
measures. Furthermore, the greater improvement
observed in the levocetirizine group was apparent
as early as after 1 week and was sustained at each
visit until 6 months, as indicated by the absence of
interaction between time and treatment effects.
This confirms the results observed when comparing
the effect of levocetirizine and placebo on the
aggregated RQLQ and SF-36 scores at each visit
separately20 and indicates that the beneficial
impact of levocetirizine on PER was extended to
each aspect of HRQOL and health status investi-
gated either by the disease-specific or the generic
instrument. Indeed, since the improvements for
levocetirizine were significantly greater than for
placebo, these findings collectively suggest that,
apart from the prevalent bothersome nasal and eye
symptoms of allergic rhinitis, the inability to
perform general/physical activities and the pre-
sence of practical problems, in particular, may
additionally contribute to both the impairment in
HRQOL/health status of PER patients and the effect
of any treatment in these patients.
Although this study has not compared HRQOL and
health status of PER patients versus those of control
subjects, our findings are nevertheless in accor-
dance with the findings of others, particularly with
respect to the individual RQLQ domains and SF-36
scales most affected. In a recent study, Downie and
colleagues30 showed that house dust mite-sensitive
PER patients were significantly more troubled by
nasal and eye symptoms, reduced productivity and
feeling of being worn out and tired, compared with
controls. Similarly, the SF-36 scores for role-
physical, role-emotional, vitality, and general
health components were significantly lower in PER
patients than in control subjects. Other studies
employing the SF-36 for assessing the health status
in subjects with intermittent and persistent rhini-
tis32 and persistent rhinitis33 have also shown thatrole-physical, role-emotional, vitality, and general
health components are particularly affected. Com-
parison of results from these later studies32,33 and
our study, however, warrants caution because these
studies were performed in SAR/PAR patients classi-
fied as ‘‘intermittent’’ and ‘‘persistent’’ rhinitis
prior to the introduction of the specific ARIA
classification, especially since IAR and PER are not
analogous with SAR and PAR, respectively.18,19
Nevertheless, the substantial placebo effect on
RQLQ scores noted in our study has also been shown
to be in line with symptomatic improvements
reported by others in placebo-treated allergic
rhinitis patients.34,35
Although the RQLQ and SF-36 have been widely
used for assessing the impact of disease and
treatment on quality of life in patients suffering
from PAR and SAR,15 there is a marked paucity of
similar data in PER patients as defined by the ARIA
criteria. While the sensitivity of these question-
naires in detecting differences in HRQOL and health
status of this patient group needs to be confirmed
in several large studies, the findings from the
present study that the RQLQ domain and overall
scores and the SF-36 summary measures and scales
were sensitive to disease severity suggests that
these instruments are suitable for assessing treat-
ment effects in patients with PER.
In the present study, a 30% relative difference in
the change from baseline of the RQLQ overall score
for active versus placebo treatment was predefined
as clinically meaningful by the study advisory board
members based on their clinical experience and
knowledge of the disease and the patients. This
clinically relevant difference was exceeded with
levocetirizine treatment reaching a relative im-
provement over placebo for the whole treatment
period of 36.4%. Moreover, a minimal important
difference (MID, i.e., the smallest difference in
score which a patient perceives as being beneficial)
of 0.5 in the change in RQLQ score from baseline
has also been used to determine the clinical
relevance of RQLQ score changes as a result of
treatment.36 Our data suggest that levocetirizine
achieves 3 times the MID (an RQLQ score of 1.49
versus baseline) which is a confirmation of the
clinical relevance of our findings. Even versus
placebo, the difference was almost one MID (0.48)
which on the one hand is a confirmation of the high
standards set by the study board members and on
the other it suggests that MID of the same
magnitude (0.5), however, versus placebo (not
versus baseline as per original research) is also
plausible and should be further evaluated.
Despite the strong evidence for positive treat-
ment effects of levocetirizine on HRQOL and health
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some limitations. Foremost, patients were allowed
to use limited amounts of nasal or ocular cromo-
glycate and in worst cases oral prednisone as rescue
medication, which could attribute to differences in
outcomes between the two treatment groups.
While this is feasible, it is more likely that the
effects of rescue medication were probably biased
in favor of improvements in placebo-treated
patients, who were shown to be using more rescue
medication over the entire 6–month study period
than levocetirizine-treated patients.20 Indeed, this
being the case it is possible that greater rescue
medication use by this group of patients may have
contributed to the substantial placebo effect noted
in this study, although this remains to be substan-
tiated in another controlled trial.
In conclusion, this study expands the findings of
the XPERT study and provides valuable insights into
the therapeutic management of HRQOL and health
status in PER patients. Results indicated that the
degree of impairment in both the HRQOL and
health status of PER patients was related to the
disease severity and that long-term treatment with
levocetirizine 5mg was effective in providing
clinically meaningful and sustained improvement
of HRQOL and to reduce the burden of disease
through improvement of health status. This is in
keeping with other studies which have also demon-
strated that the effects of long-term regular daily
administration of an H1-antihistamine did not wane
and were beneficial in treatment of AR and/or its
comorbid diseases.37,38 We could confirm that RQLQ
is a very sensitive disease-specific instrument. The
generic SF-36 instrument showed a lower sensitiv-
ity, although certain of its scales (e.g. role-
physical, role-emotional and general health) were
more sensitive than others.Acknowledgments
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